What will be the impact of US tariffs on CDMOs of injectables and on the decision-making of pharma companies on in-sourced/outsourced activity overall and in key geographic markets: Europe, Canada, India and China? How will major segments, innovator drug and generics/biosimilar be affected? Featuring Ian Tzeng, Managing Director and Partner, L.E.K. Consulting, where he focuses on healthcare and life sciences, including pharmaceuticals and vaccines, and leads L.E.K.’s Pharmaceutical Con...